UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): July 19, 2016

Amedica Corporation

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)

001-33624 (Commission File Number)

84-1375299 (IRS Employer Identification No.)

1885 West 2100 South
Salt Lake City, UT
(Address of principal executive offices)

84119 (Zip Code)

Registrant's telephone number, including area code: (801) 839-3500

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ($\underline{\text{see}}$ General Instruction A.2. below):

[]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 4.01. Changes in Registrant's Certifying Accountant

Mantyla McReynolds, LLC ("Mantyla"), the Company's independent registered public accountants, merged with BDO USA, LLP ("BDO") on July 1, 2016. As a result of this transaction, on July 19, 2016 Amedica Corporation (the "Company") received notice that instead of Mantyla, BDO would now stand for appointment as the Company's independent registered public accountants for the fiscal year ending December 31, 2016. Effective July 22, 2016, the Company, after review and approval of the Company's Audit Committee, appointed BDO as the Company's new independent registered public accounting firm for and with respect to the fiscal year ending December 31, 2016.

Mantyla's reports on the Company's financial statements as of and for the fiscal years ended December 31, 2015 and 2014 contained an emphasis paragraph that raised substantial doubt about its ability to continue as a going concern. Other than the going concern matter, the reports of Mantyla on the financial statements of the Company for the fiscal years ended December 31, 2015 and 2014 did not contain any other adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles.

During the Company's fiscal years ended December 31, 2015 and 2014 and through July 19, 2016, there were no disagreements between the Company and Mantyla on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Mantyla, would have caused Mantyla to make reference to the subject matter of the disagreements in connection with its audit reports on the Company's financial statements. During the Company's past fiscal years ended December 31, 2014 and 2015 and the interim period through July 19, 2016, Mantyla did not advise the Company of any of the matters specified in Item 304(a)(1)(v) of Regulation S-K.

The Company provided Mantyla with a copy of this report on Form 8-K in accordance with Item 304(a) of Regulation S-K prior to its filing with the Securities and Exchange Commission and requested that Mantyla furnish the Company with a letter addressed to the Securities and Exchange Commission stating whether it agrees with the above statements and, if it does not agree, the respects in which it does not agree. A copy of the letter from Mantyla is filed as Exhibit 16.1 hereto.

During the Company's two most recently completed fiscal years and through the date of engagement of BDO, neither the Company nor anyone on behalf of the Company consulted with BDO regarding (a) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company's financial statements as to which the Company received a written report or oral advice that was an important factor in reaching a decision on any accounting, auditing or financial reporting issue; or (b) any matter that was the subject of a disagreement or a reportable event as defined in Items 304(a)(1)(iv) and (v), respectively, of Regulation S-K.

Section 9 — Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
16.1	Mantyla Letter of Concurrence

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Amedica Corporation

Date: July 22, 2016 By: /s/ Ty Lombardi

Ty Lombardi Chief Financial Officer

EXHIBIT INDEX

EXHIBIT	DESCRIPTION
16.1	Mantyla Letter of Concurrence



Exhibit 16.1

July 22, 2016

Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549

Mantyla M'Reynolds LLC

We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred on July 19, 2016, to be filed by our former client, Amedica Corporation. We agree with the statements made in response to that Item insofar as they relate to our Firm.

Very truly yours,

Mantyla McReynolds, LLC